EsoBiotec Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 12

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1B

EsoBiotec General Information

Description

Developer of immunotherapies designed to make cancer treatments more accessible, effective, and affordable. The company develops drugs and therapeutics that are cost-effective to maximize accessibility to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients, enabling patients to have access to cancer treatments at lower costs.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Rue André Dumont 5
  • 1435 Mont-Saint-Guibert
  • 6041 Charleroi
  • Belgium
Primary Industry
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • Rue André Dumont 5
  • 1435 Mont-Saint-Guibert
  • 6041 Charleroi
  • Belgium

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EsoBiotec Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 19-May-2025 $1B Completed Generating Revenue
4. Early Stage VC (Series A) 27-Aug-2024 Completed Generating Revenue
3. Early Stage VC 14-Jun-2022 Completed Generating Revenue
2. Seed Round 30-Sep-2021 $2.65M $2.65M Completed Generating Revenue
1. Grant 01-Jan-2021 $3.65M Completed Generating Revenue
To view EsoBiotec’s complete valuation and funding history, request access »

EsoBiotec Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference Shares
To view EsoBiotec’s complete cap table history, request access »

EsoBiotec Patents

EsoBiotec Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024308616-A1 Viral vector and producer cell Pending 30-Jun-2023
EP-4484563-A1 Viral vector and producer cell Active 30-Jun-2023
EP-4484563-B1 Viral vector and producer cell Active 30-Jun-2023
EP-4544068-A1 Viral vector and producer cell Pending 30-Jun-2023
ES-3055997-T3 Viral vector and producer cell Active 30-Jun-2023 C12N15/86
To view EsoBiotec’s complete patent history, request access »

EsoBiotec Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EsoBiotec Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Carbon ( Belgium ) Venture Capital Minority
Invivo Partners Venture Capital Minority
ORSA FUND Venture Capital Minority
Société Régionale d'Investissement de Wallonie Growth/Expansion Minority
Thuja Capital Management Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

EsoBiotec FAQs

  • When was EsoBiotec founded?

    EsoBiotec was founded in 2020.

  • Where is EsoBiotec headquartered?

    EsoBiotec is headquartered in Charleroi, Belgium.

  • What is the size of EsoBiotec?

    EsoBiotec has 12 total employees.

  • What industry is EsoBiotec in?

    EsoBiotec’s primary industry is Biotechnology.

  • Is EsoBiotec a private or public company?

    EsoBiotec is a Private company.

  • What is the current valuation of EsoBiotec?

    The current valuation of EsoBiotec is .

  • What is EsoBiotec’s current revenue?

    The current revenue for EsoBiotec is .

  • How much funding has EsoBiotec raised over time?

    EsoBiotec has raised $20.9M.

  • Who are EsoBiotec’s investors?

    Carbon ( Belgium ), Invivo Partners, ORSA FUND, Société Régionale d'Investissement de Wallonie, and Thuja Capital Management are 5 of 8 investors who have invested in EsoBiotec.

  • When was EsoBiotec acquired?

    EsoBiotec was acquired on 19-May-2025.

  • Who acquired EsoBiotec?

    EsoBiotec was acquired by AstraZeneca.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process